ReviewLung Cancer (Auckland, N.Z.)2017
Review in Lung Cancer (Auckland, N.Z.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- A novel nanotechnology-based strategy using CNT-FeJournal, genetic engineering & biotechnology · 2026Article
- A Case of PrimaryCurrent oncology (Toronto, Ont.) · 2026Article
- <p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>.Oncology reports · 2026Review
- In silico and In vitro studies of EGFR kinase and Anilide derivatives as inhibitors against Breast Cancer.Biotechnology notes (Amsterdam, Netherlands) · 2026Article
- Translating Liquid Biopsy into Practice- The Promise and Challenges of Circulating Tumor Cells in Ovarian and Lung Cancer Management.Biomarker insights · 2026Review
- The lncRNA PACER Regulates Lung Adenocarcinoma Phenotypes via COX-2 Signaling and RNA Structural Dynamics.bioRxiv : the preprint server for biology · 2025Article
- Potential supplementary tumor markers for liquid biopsy in non-small cell lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Review
- EGFR signaling and pharmacology in oncology revealed with innovative BRET-based biosensors.Communications biology · 2024Article
- Schizandrin A induces non-small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation.Cancer medicine · 2024Article
- Ku-DNA binding inhibitors modulate the DNA damage response in response to DNA double-strand breaks.NAR cancer · 2023Article
- Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.BMC medicine · 2023Article
- MonitoringFrontiers in oncology · 2023Review
- Targeting HER3 to overcome EGFR TKI resistance in NSCLC.Frontiers in immunology · 2023Review
- Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed withJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches forInternational journal of molecular sciences · 2022Article
- New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFRACS omega · 2022Article
- Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.Molecular and clinical oncology · 2022Article
- Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.Biomolecules & therapeutics · 2022Review
- PACER lncRNA regulates COX-2 expression in lung cancer cells.Oncotarget · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancers that harbor activating mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.